ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Rational Design and Synthesis of Androgen Receptor-Targeted Nonsteroidal Anti-Androgen Ligands for the Tumor-Specific Delivery of a Doxorubicin−Formaldehyde Conjugate

View Author Information
Department of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309-0215, and Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado 80262
Cite this: J. Med. Chem. 2003, 46, 24, 5258–5270
Publication Date (Web):October 18, 2003
Copyright © 2003 American Chemical Society

    Article Views





    Other access options
    Supporting Info (1)»


    Abstract Image

    The synthesis and preliminary evaluation of a doxorubicin−formaldehyde conjugate tethered to the nonsteroidal antiandrogen, cyanonilutamide (RU 56279), for the treatment of prostate cancer are reported. The relative ability of the targeting group to bind to the human androgen receptor was studied as a function of tether. The tether served to attach the antiandrogen to the doxorubicin−formaldehyde conjugate via an N-Mannich base of a salicylamide derivative. The salicylamide was selected to serve as a trigger release mechanism to separate the doxorubicin−formaldehyde conjugate from the targeting group after it has bound to the androgen receptor. The remaining part of the tether consisted of a linear group that spanned from the 5-position of the salicylamide to the 3‘-position of cyanonilutamide. The structures explored for the linear region of the tether were derivatives of di(ethylene glycol), tri(ethylene glycol), N,N‘-disubstituted-piperazine, and 2-butyne-1,4-diol. Relative binding affinity of the tethers bound to the targeting group for human androgen receptor were measured using a 3H-Mibolerone competition assay and varied from 18% of nilutamide binding for the butynediol-based linear region to less than 1% for one of the piperazine derivatives. The complete targeted drug with the butynediol-based linear region has a relative binding affinity of 10%. This relative binding affinity is encouraging in light of the cocrystal structure of human androgen receptor ligand binding domain bound to the steroid Metribolone which predicts very limited space for a tether connecting the antiandrogen on the inside to the cytotoxin on the outside.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

     University of Colorado Health Sciences Center.


     Corresponding author. Phone 303-492-6193, fax 303-492-5894, e-mail [email protected].

     University of Colorado.

    Supporting Information Available

    Jump To

    1H NMR spectra for all products and isolated intermediates; semilogarithmic IC50 determinations. This material is available free of charge via the Internet at

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:

    Cited By

    This article is cited by 27 publications.

    1. Cunyuan Zhao, Yuankai Wang, Quan Pham, Changhang Dai, Abhishek Chatterjee, Masayuki Wasa. Chemical Tagging of Bioactive Amides by Cooperative Catalysis: Applications in the Syntheses of Drug Conjugates. Journal of the American Chemical Society 2023, 145 (26) , 14233-14250.
    2. Xiaodong Qin, Lei Fang, Jian Zhao, Shaohua Gou. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor. Inorganic Chemistry 2018, 57 (9) , 5019-5029.
    3. Paul M. Levine, Michael J. Garabedian, and Kent Kirshenbaum . Targeting the Androgen Receptor with Steroid Conjugates. Journal of Medicinal Chemistry 2014, 57 (20) , 8224-8237.
    4. Berkley E. Gryder, Michelle J. Akbashev, Michael K. Rood, Eric D. Raftery, Warren M. Meyers, Paulette Dillard, Shafiq Khan, and Adegboyega K. Oyelere . Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors. ACS Chemical Biology 2013, 8 (11) , 2550-2560.
    5. Yanmei Dong, Yu Zhu, Jing Li, Qing-Hui Zhou, Chao Wu, and David Oupický . Synthesis of Bisethylnorspermine Lipid Prodrug as Gene Delivery Vector Targeting Polyamine Metabolism in Breast Cancer. Molecular Pharmaceutics 2012, 9 (6) , 1654-1664.
    6. Marco Zuccolo, Noemi Arrighetti, Paola Perego, Diego Colombo. Recent Progresses in Conjugation with Bioactive Ligands to Improve the Anticancer Activity of Platinum Compounds. Current Medicinal Chemistry 2022, 29 (15) , 2566-2601.
    7. Michael L. Mohler, James T. Dalton. Modulation of the Androgen Receptor Axis. 2021, 1-103.
    8. Nelin Hacıoğlu, Tuğba Güngör, Esra Tokay, Ferah Cömert Önder, Mehmet Ay, Feray Köçkar. Synthesis and biological evaluation of 2,4,6-trinitroaniline derivatives as potent antitumor agents. Monatshefte für Chemie - Chemical Monthly 2020, 151 (10) , 1629-1641.
    9. Pedavenkatagari Narayana Reddy, Pannala Padmaja, Bobbala Ramana Reddy, Surender Singh Jadav. Synthesis, in vitro antiproliferative activity, antioxidant activity and molecular modeling studies of new carbazole Mannich bases. Medicinal Chemistry Research 2017, 26 (10) , 2243-2259.
    10. Samira Bagheri, Nurhidayatullaili Muhd Julkapli, Wageeh Abdulhadi Yehya Dabdawb, Negar Mansouri. Biodiesel ‐Derived Raw Glycerol to Value‐Added Products: Catalytic Conversion Approach. 2017, 309-365.
    11. Xiaohong Tian, Yang He, Jinming Zhou. Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Frontiers in Pharmacology 2015, 6
    12. Gheorghe Roman. Mannich bases in medicinal chemistry and drug design. European Journal of Medicinal Chemistry 2015, 89 , 743-816.
    13. Yong-Jiang Zhao, Wei Wei, Zhi-Guo Su, Guang-Hui Ma. Poly (ethylene glycol) prodrug for anthracyclines via N-Mannich base linker: Design, synthesis and biological evaluation. International Journal of Pharmaceutics 2009, 379 (1) , 90-99.
    14. Nima Sharifi, Ernest Hamel, Markus A. Lill, Prabhakar Risbood, Charles T. Kane, Md Tafazzal Hossain, Amanda Jones, James T. Dalton, William L. Farrar. A bifunctional colchicinoid that binds to the androgen receptor. Molecular Cancer Therapeutics 2007, 6 (8) , 2328-2336.
    15. W. H. Bisson, A. V. Cheltsov, N. Bruey-Sedano, B. Lin, J. Chen, N. Goldberger, L. T. May, A. Christopoulos, J. T. Dalton, P. M. Sexton, X.-K. Zhang, R. Abagyan. Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proceedings of the National Academy of Sciences 2007, 104 (29) , 11927-11932.
    16. Suzanne M. Cutts, Lonnie P. Swift, Vinochani Pillay, Robert A. Forrest, Abraham Nudelman, Ada Rephaeli, Don R. Phillips. Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate. Molecular Cancer Therapeutics 2007, 6 (4) , 1450-1459.
    17. Tad H. Koch, Benjamin L. Barthel, Brian T. Kalet, Daniel L. Rudnicki, Glen C. Post, David J. Burkhart. Anthracycline–Formaldehyde Conjugates and Their Targeted Prodrugs. 2007, 141-170.
    18. Glen C. Post, Benjamin L. Barthel, David J. Burkhart, John R. Hagadorn, Tad H. Koch. Doxazolidine, a Proposed Active Metabolite of Doxorubicin That Cross-links DNA. Journal of Medicinal Chemistry 2005, 48 (24) , 7648-7657.
    19. Jin Kyu Kim, Udaya S. Toti, Rita Song, Youn Soo Sohn. A macromolecular prodrug of doxorubicin conjugated to a biodegradable cyclotriphosphazene bearing a tetrapeptide. Bioorganic & Medicinal Chemistry Letters 2005, 15 (15) , 3576-3579.
    20. Rita Song, Yong Joo Jun, Ju Ik Kim, Changbae Jin, Youn Soo Sohn. Synthesis, characterization, and tumor selectivity of a polyphosphazene–platinum(II) conjugate. Journal of Controlled Release 2005, 105 (1-2) , 142-150.
    21. Suzanne Cutts, Abraham Nudelman, Ada Rephaeli, Don Phillips. The Power and Potential of Doxorubicin-DNA Adducts. IUBMB Life (International Union of Biochemistry and Molecular Biology: Life) 2005, 57 (2) , 73-81.
    22. Patrick J. Burke, Brian T. Kalet, Tad H. Koch. Antiestrogen Binding Site and Estrogen Receptor Mediate Uptake and Distribution of 4-Hydroxytamoxifen-Targeted Doxorubicin−Formaldehyde Conjugate in Breast Cancer Cells. Journal of Medicinal Chemistry 2004, 47 (26) , 6509-6518.
    23. David J. Burkhart, Brian T. Kalet, Michael P. Coleman, Glen C. Post, Tad H. Koch. Doxorubicin-formaldehyde conjugates targeting αvβ3 integrin. Molecular Cancer Therapeutics 2004, 3 (12) , 1593-1604.
    24. Peter S. Cogan, Tad H. Koch. Studies of Targeting and Intracellular Trafficking of an Anti-Androgen Doxorubicin−Formaldehyde Conjugate in PC-3 Prostate Cancer Cells Bearing Androgen Receptor-GFP Chimera. Journal of Medicinal Chemistry 2004, 47 (23) , 5690-5699.
    25. Yeong-Sang Kim, Rita Song, Chong Ock Lee, Youn Soo Sohn. Synthesis and biological activity of novel platinum(II) complexes of glutamate tethered to hydrophilic hematoporphyrin derivatives. Bioorganic & Medicinal Chemistry Letters 2004, 14 (11) , 2889-2892.
    26. Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, Gaetano Cairo, Luca Gianni. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews 2004, 56 (2) , 185-229.
    27. Jeffrey P. Krise, Reza Oliyai. Prodrugs of Amines. , 801-831.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    Pair your accounts.

    Export articles to Mendeley

    Get article recommendations from ACS based on references in your Mendeley library.

    You’ve supercharged your research process with ACS and Mendeley!

    STEP 1:
    Click to create an ACS ID

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

    Your Mendeley pairing has expired. Please reconnect